Drug Profile
PD 083176
Alternative Names: PD 83176Latest Information Update: 19 Oct 2000
Price :
$50
*
At a glance
- Originator Pfizer
- Class Oligopeptides
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 19 Oct 2000 No-Development-Reported for Breast cancer treatment in USA (Unknown route)
- 21 Jun 2000 Warner-Lambert has merged with Pfizer
- 12 Oct 1998 Preclinical development for Breast cancer treatment in USA (Unknown route)